文献速递湿疹皮炎与荨麻疹

度普利尤单抗在中国特应性皮炎患者中的真实世界疗效与安全性:一项单中心、前瞻性、开放标签研究

Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-04-01

该单中心前瞻性开放标签研究纳入138例中重度特应性皮炎患者,接受度普利尤单抗治疗16周。第16周时64.5%患者湿疹面积和严重度指数较基线改善≥75%,60.9%达到研究者总体评估0/1分。34.1%患者报告不良事件,面部红斑和眼部症状最常见。

要点

  • 第16周64.5%患者EASI较基线改善≥75%,60.9%达到IGA 0/1分。
  • 女性(校正OR 2.12)和BMI<24(OR 3.03)为良好反应的潜在预测因素。
  • 34.1%患者报告不良事件,面部红斑13%、眼部症状10.9%最常见。

核心结论

  • 度普利尤单抗在中国特应性皮炎患者的真实世界实践中显示出良好疗效和可耐受的安全性。

研究设计与样本

  • 单中心、前瞻性、开放标签研究,纳入138例中重度特应性皮炎患者,在中国上海华山医院接受度普利尤单抗治疗,随访16周。

主要发现

  • 第16周时64.5%患者湿疹面积和严重度指数较基线改善≥75%,60.9%患者达到研究者总体评估0/1分(或较基线降低≥2分)。
  • 躯干疗效评分中位下降96.24%(四分位距89.04%至100%),较其他身体部位下降最显著。
  • 女性(校正OR 2.12,95%CI 0.79-5.74)和BMI<24(OR 3.03,95%CI 1.19-7.68)为良好反应的潜在预测因素;年龄>60岁(OR 0.57,95%CI 0.10-3.28)预测反应不佳。
  • 34.1%患者报告不良事件,面部红斑(13%)和眼部症状(10.9%)最常见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dupilumab, an antibody against interleukin-4 receptor α, has demonstrated elegant efficacy and safety profiles in patients with moderate-to-severe atopic dermatitis (AD). However, the efficacy of dupilumab varies among AD patients, and compared with the Caucasian population, the data of dupilumab for Asian people, especially Chinese AD patients, is very limited. OBJECTIVE: To investigate the efficacy and safety of dupilumab for AD in a real-world Chinese single-centre prospective cohort. METHODS: We enrolled 138 moderate-to-severe AD patients receiving dupilumab treatment at Huashan Hospital, Shanghai, China in this 16-week, single-centre, prospective, open-label study. The patients were evaluated at baseline, 2, 4, 8 and 16 weeks after first dupilumab administration for multiple physician- and patient-reported outcome measures. Blood eosinophil counts and total serum IgE were measured. RESULTS: There were early and sustained improvement in all the efficacy measures evaluated after dupilumab administration. 64.5% AD patients achieved an improvement of ≥75% in the Eczema Area and Severity Index from baseline, and 60.9% patients achieved the Investigator's Global Assessment 0/1 (or a reduction of ≥2 points from baseline) at week 16. The trunk demonstrated the most significantly decreased efficacy score [median decreased 96.24% (interquartile range, 89.04 to 100%)] compared with other body sites. Female (adjusted OR: 2.12, 95% confidence interval: 0.79-5.74) and body mass index (BMI) <24 (3.03; 1.19-7.68) were identified as potential predictive factors of good response; while age >60 (0.57; 0.10-3.28) predicted poor response. Adverse events were reported by 34.1% patients, and facial erythema (13%) and ocular symptoms (10.9%) were the most common. CONCLUSIONS: Dupilumab demonstrated favourable efficacy and well-tolerated safety in Chinese AD patients in real-world practice.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Gu C, Wu Y, Luo Y, et al. Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study. J Eur Acad Dermatol Venereol. 2022. PMID: 35344634. doi:10.1111/jdv.18109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。